Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Your health history, goals, medications, and eligibility are reviewed
Table of Contents Understanding Wegovy and Its Role in Weight Management During Perimenopause How Perimenopause Affects Weight and Metabolism Clinical Evidence for Wegovy Use in Perimenopausal Women Safety Considerations and Contraindications for Wegovy in Perimenopause Practical Guidance: Using Wegovy During the Perimenopausal Transition Scientific References Frequently Asked Questions Understanding Wegovy and Its Role in Weight Management During Perimenopause Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
This multi-action formula works at a deeper level to repair damaged skin, brighten tone, and restore natural radiance
It can interact with metformin (Glucophage), most commonly taken for diabetes, or proton pump inhibitors that are taken for gastric issues
doi: 10.3390/antiox10121931 33 OsrioJStillerKTReitenB-KKolarevicJJohansenL-HAfonsoFet al
